Aphios® Pharma LLC is empowering patients with extended-release cannabinoid nanoparticles to sustainably combat chronic addiction, pain, anxiety and other debilitating central nervous system disorders.

Problem

While Cannabis and medical marijuana can assist with Central Nervous System (CNS) disorders, their effects are often inconsistent and short-lived.

Solution

Rebalance our endocannabinoid system: Our approach sets us apart from other cannabis companies by utilizing patented nanotechnologies to sustain the release of cannabinoids in the body, effectively treating chronic pain, anxiety, addiction, and other CNS disorders.

• Endocannabinoid System and Health: Imbalances in our internal cannabinoid or endocannabinoid system can lead to health issues and impair our ability to heal.
• Challenges with Cannabis: Cannabis can help but it interacts complexly with our nervous systems with less than 10% remaining in the body, making it short-lived and non-specific in effect.
• Nanotechnology for Chronic Diseases: We use patented nanoparticles to maintain specific cannabinoids in the body longer and sustain their release over days and weeks.
• Our technology platforms of drug discovery, drug manufacturing and nanotechnology drug delivery are protected by 17 US patents.

Market

• The total available marketplace (TAM) of this market opportunity at the time of launch of our first product in 2033 is approximately 93 billion dollars. We estimate that the serviceable addressable market (SAM) is about 1/3 or $39 billion and our serviceable obtainable market (SOM) in the United States alone is about $3 billion.
• About 35% of the SOM or $1 billion is estimated for opioid use disorder with cancer pain accounting for about 22% followed by anxiety, Multiple Sclerosis and epilepsy, each with about 14 to 15% of the marketplace.

These might seem like varied issues, but they are all connected to our internal or inherent endocannabinoid system that is part of our central and peripheral  nervous systems.

Competition

• Our primary competition is Jazz Pharmaceuticals and GW Pharma who developed an immediate release CBD drug called Epidiolex for Dravet’s syndrome that affects a subset of children with epilepsy. As a result, Jazz purchased GW Pharma for $7.2 billion a few years ago.
• Other competitors are pharmaceutical companies such as Abbvie producing synthetic immediate release cannabinoids and companies such as Merck, Pfizer and Biogen using synthetic chemicals with huge side effects and addictive potential for similar indications.

We differ from these companies and Jazz by using nanoparticles to sustain cannabinoids in the body longer and extended release to alleviate suffering from chronic pain, addiction and anxiety.

Funding

Aphios Pharma LLC is raising $0.6M through Regulation Crowdfunding, which is available to investors in the general public, and $30M in Regulation D, which is only available to accredited investors and investment institutions, to scale manufacturing, conduct IND-enabling studies and file an IND with the FDA, and complete Phase 2 clinical trials.